| Objective:To observe BYHWD of good blood glucose control in type 2 diabeticperipheral neuropathy (diabetic Peripheral Neuropathy, DPN) patientsRheolegy, lipids, HbAlc, Nerve conduction velocity and the impact ofclinical symptoms. To analysis BYHWD the mechanism, and to explore theclinical side of the application.Methods:1 The clinical data: Those cases were diagnosed as type 2 diabeticperipheral neuropathy patients and were collected in the period from July2005 to January,200, patient and out-patien in the hospital, and glycemiccontrol in a more satisfactory level (fasting glucose≤7.0mmol/L, 2hPG≤8mmol/L) reaches more than one month. The patients were randomlydivided into a control group and treatment group. Treatment of 40 patients,male 18, female 22; 42-87 years of age (mean age 66.68 years); 6-18,diabetes duration, average 10.6 years. The control group of 40 cases, ofwhich 19 men and 21 women; 43-87 years of age (mean age 66.9 years);diabetes duration 5 to 19 years, an average of 10.8 years. Two groups ofpatients in terms of gender, age, duration of diabetes, statistically,the difference was not significant (P＞0.05), comparable.2. Treatment of two patients were routine diet control, exerciseappropriate, and as experimental service before the hypoglycemic drugs,of glycemic control in a more satisfactory level (fasting glucose≤7.0mmol/L, 2hPG≤8mmol/L). Application of the control group Artemisinsurable Methycobal tablets (Japan-Wood Manufacturing Co., Ltd.)500ug, PO. tid. One month for a course of treatment, Continuous use of twocourses. Treatment in the control group on the basis of taking BYHWD:Angelica30g Astragalus 10g Chishao10g Dragon 10g Chuanxiong 6gsafflower 10g Taoren 6g. Those Chinese traditional medicine were fired in the hospital preparation room as Chinese soups, and divided into twobags packed.In the morning and evening taking a bag.One month for a courseof treatment. Continuous use of two courses.3 The curative effect3.1 Effect of clinical symptoms: a limb numbness and lancinating painor burning,flashing a knife-like pain or pain, with or without muscleatrophy weakness, depth of feeling significantly diminish.3.2 clinical signs: tendon reflex, knee jerk diminish or disappear; Theinspection had limbs nerve conduction velocity was delayed, Theincubation period is extended, and lower voltage electrophysiologicalabnormalities.3.3 Related laboratory examinations: Rheolegy, lipids, HbAlc, nerveconduction velocity, before treatment and after treatment of theinspections.4 security, laboratory observation4.1: blood, urine, in order; Liver and kidney function; ECG examination.Coagulation function. Routine examinations once a week, four weeks after2～4 weeks for a check-up. Liver and kidney function every 4 weeks fora check-up. Coagulation 2～4 weeks for a check-up.4.2 Adverse Reactions: To observe patients taking the drug after anydiscomfort, and the combination of blood, liver and kidney function andblood coagulation inspection of the observation of a non-toxic drug sideeffects. 5 Statistical Methods: SPSS12.0 statistical analysis softwarecalculation. All measurement data with (?)±S (mean±standard deviation),t test; Count information is X2 test; grading information is Riditanalysis.Result:1. control group and treatment group clinical symptoms and signs comparedchanges: 2 months after treatment, treatment and control groups of the main symptoms and signs than before treatment was significantly improved,treatment of the symptoms and signs of improvement in the total wassignificantly higher than the control group, P＜0.01.2. Blood theology control group and treatment group have varying degreesof change. By the t-test, whole blood viscosity, high shear, low shear,Plasma viscosity and hematocrit before and after treatment weresignificantly different (P＜0.01). After treatment, the treatment groupwas better than in the control group, P＜0.05.3. After treatment glycosylated hemoglobin had dropped, but the two groupshad no significant difference.4. Control group and a treatment group and control group lipid treatmentgroup have varying degrees of change. However, the two groups had nosignificant difference.5. After the treatment group and control group of motor conductionvelocity (MNCV) and sensory conduction velocity (exhibited) showed someimprovements. However, the treatment group and the control group motorconduction velocity (MNCV) and sensory conduction velocity (exhibited),the a significant difference (P＜0.05)Conclusion:The results showed: BYHWD can improve motor and sensory nerve conductionvelocity, improvement in patients with type 2 diabetes peripheralneuropathy nerve function. Can be improved in patients with type 2diabetes blood hypercoagulability of blood theology which whole bloodviscosity high and low shear, Plasma viscosity and hematocrit, and otherindicators were markedly lower. On serum lipids, HbAlc a certain effect,but no significant change. Affirmed BYHWD of patients with type 2 diabetesperipheral neuropathy unique efficacy, worthy of further explore theirclinical value. |
PDF Full Text Request